Low dose interferon gamma for refractory Crohn's disease.
H Debinski, A Forbes, MA Kamm
Ital J Gastroenterol Hepatol | Published : 1997
AIM: Direct cytokine modulation may benefit patients with inflammatory bowel disease. PATIENTS: Subcutaneous interferon gamma (1.5 microgram/kg) was given three times a week in an open pilot study to four patients with active Crohn's disease unresponsive to standard immunosuppressive drug treatment. RESULTS: In one patient, the C-reactive protein and Crohn's disease activity index returned to normal and the patient became asymptomatic. The other three patients did not complete the 12-week treatment course, one because of drug failure, one because of drug side effects, and one because of incidental disease. However, the Crohn's disease activity index fell substantially and the C-reactive prot..View full abstract